


Prevention Paradigm 2016 & beyond







Different Strokes for Different Folks

Method	Contraception	HIV Prevention
Behaviour	✓	✓
Barrier Methods	✓	✓
Gels	✓	✓ – ?
Rings	✓	✓
Oral pill	✓	✓
Injectables	✓	
Implants	✓	
Surgical procedures	✓	✓
Treatment		✓



Next Up

2 Ongoing and Planned Efficacy Trials (July 2016)

Strategy	Trial	Product	Number ppts	Population	Status (start-end)	Location
 Antibody	HVTN 704/ HPTN 085	VRC01 antibody, infused every two months	2,700	Men and transgender persons who have sex with men	Enrolling: Apr. 2016–Sept. 2020	Brazil, Peru, US
 Antibody	HVTN 703/ HPTN 081		1,500	Sexually active women	Enrolling: May 2016–Jul. 2020	Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe
 Preventive HIV vaccine	HVTN 702	ALVAC/gp120 MF59 adjuvant boost, five doses over 12 months	5,400	Sexually active hetero- sexual women and men	Projected start Nov. 2016–End 2020	South Africa
 Long-acting injectable	HPTN 083	Cabotegravir injections every two months	4,500	Men and transgender persons who have sex with men	Projected start Q3/4 2016; OR projected end June 2020	~40 sites in North and South America, South Africa and Asia
 Long-acting injectable	HPTN 084	Cabotegravir injections; schedule to be confirmed, either every two or three months	TBD	Sexually active women	Potential start in 2017	Southern and East African countries TBD
 Preventive HIV vaccine	TBD	Ad26/MVA boost	TBD	TBD	Potential start in 2017	US, Latin American, Southern and East African countries TBD

For the latest trial updates visit www.avac.org/pxrd.

The MTN-034 Landscape

Ongoing and Planned Trials and Demonstration Projects in trial-site communities (from 2017)

PrEP in adolescents

● HPTN 082

South Africa: Cape Town-Ema, Wits RHI; Zimbabwe: Spilhaus

● EMPOWER

South Africa: Wits RHI

● 3Ps (conditional incentives)

South Africa: Cape Town Masi

● DREAMS

Kenya: Homa Bay, **Kisumu**, Siaya, Nairobi; South Africa: Joburg, Durban/KZN;

Zimbabwe: multiple; none in Harare

● Bridge to Scale - Kenya

● POWER (microbicides, PrEP for 16-25 y/o AGYW)

South Africa: Cape Town, Joburg; Kenya: Kisumu

Other trials

● HPTN 076 (injectable ARV)

South Africa: Cape Town-Ema; Zimbabwe: Spilhaus

● AMP (antibody infusion - HVTN 703/HPTN 081)

Kenya: Kisumu; South Africa: 6 sites, including MRC Chatsworth (Durban); Wits RHI (Joburg); Groote Schuur (Cape Town);

Zimbabwe: Seke South, Spilhaus, UZ- Parirenyatwa

● HVTN 702 (vaccine)


South Africa: 15 sites, including 3 in Cape Town: Cape Town-Ema, Groote Schuur, Khayelitsha; 3 in Durban: eThekwin, MRC Isipingo, MRC Verulam; and 2 in Joburg (Soweto)

Ring open-label trials



HOPE is being conducted at MTN-034 trial sites in South Africa and Zimbabwe

DREAM is taking place in the Cape Town area and in KZN



MTN-034 sites

- Kenya • Kisumu
- Zimbabwe • Spilhaus (Harare)
- South Africa • Cape Town - Emavundleni
 - Durban - MRC Chatsworth
 - Johannesburg - Wits RHI